Unknown PHASE2 INTERVENTIONAL 1-arm NCT05346874

Neoadjuvant TACiE in Locally Advanced Gastric Cancer

Neoadjuvant Transcatheter Arterial Chemoinfusion and Embolism (TACiE) for Patients With Locally Advanced Adenocarcinoma of Stomach and Gastroesophageal Junction: a Prospective, Phase 2, Single Arm Trial.

Sponsor: Shanghai Zhongshan Hospital

Conditions Gastric Cancer

Interventions Oxaliplatin Teysuno Transarterial chemoembolization (TACE)

Updated 5 times since 2022 Last updated: May 25, 2022 Started: Jun 1, 2022 Primary completion: Jun 1, 2023 Completion: May 1, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Gastric Cancer, this trial is ongoing. The trial is conducted by Shanghai Zhongshan Hospital and has accumulated 5 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Jun 2025 — Present [monthly]

Unknown PHASE2

Status: Not Yet Recruiting → Unknown
Sep 2024 — Jun 2025 [monthly]

Not Yet Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE2
Jun 2022 — Jul 2024 [monthly]

Not Yet Recruiting PHASE2
May 2022 — Jun 2022 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shanghai Zhongshan Hospital

Data source: Shanghai Zhongshan Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China